Hypertension:微血管功能障碍与较差的认知表现有关

2019-11-20 xing.T MedSci原创

该研究的结果表明,微血管功能障碍与较差的认知表现有关。

血管功能障碍可能与较差的认知表现有关。以前大多数研究都没有针对重要的混杂因素进行调整,仅评估了微血管功能障碍的个别指标,并得出了不一致的结果。近日,心血管权威杂志Hypertension上发表了一篇研究文章,在基于人群的马斯特里赫特研究中,研究人员评估了一套全面的微血管功能障碍测量指标与认知能力之间的关联。

研究人员使用的横断面数据包括3011名参与者(年龄为59.5±8.2岁;女性占48.9%;26.5%为2型糖尿病患者)。微血管功能障碍的测量指标包括脑小血管疾病的磁共振成像特征、微血管功能障碍的血浆生物标志物、蛋白尿、闪烁光引起的视网膜小动脉和静脉扩张反应以及加热诱导的皮肤充血。这些指标总结为微血管功能障碍综合评分。评估的认知领域为记忆力、处理速度和执行功能。研究人员计算出一个认知功能得分,作为这三个认知领域得分的总和。

研究人员发现微血管功能障碍评分与较差的认知功能评分(标准β为-0.087[95%CI为-0.127至-0.047])相关,且独立于年龄、文化程度、性别、2型糖尿病、吸烟、饮酒、高血压、总/HDL(高密度脂蛋白)胆固醇比值、甘油三酯、降脂药物、既往心血管疾病、抑郁症和低度炎症的血浆生物标志物。对于微血管功能障碍评分每增加一个SD,微血管功能障碍评分与认知功能评分之间关联的完全调整β系数相当于衰老2年(1-3年)。微血管功能障碍评分与较差的记忆力和处理速度有关,但与较差的执行功能无关。

该研究的结果表明,微血管功能障碍与较差的认知表现有关。 

原始出处:

Sytze P. Rensma.et al.Microvascular Dysfunction Is Associated With Worse Cognitive Performance The Maastricht Study.Hypertension.2019.https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.119.13023

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1718700, encodeId=10841e1870047, content=<a href='/topic/show?id=a93250e8239' target=_blank style='color:#2F92EE;'>#微血管功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50782, encryptionId=a93250e8239, topicName=微血管功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c032593421, createdName=zz81, createdTime=Wed May 27 23:52:00 CST 2020, time=2020-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018097, encodeId=05c5201809e5f, content=<a href='/topic/show?id=9f53912654e' target=_blank style='color:#2F92EE;'>#认知表现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91265, encryptionId=9f53912654e, topicName=认知表现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Thu Mar 26 04:52:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728203, encodeId=448e1e2820393, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Sep 03 10:52:00 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039123, encodeId=b5d020391230a, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Thu Dec 05 06:52:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365386, encodeId=00a3136538616, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Fri Nov 22 11:52:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421264, encodeId=84af142126477, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Fri Nov 22 11:52:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501416, encodeId=2b5f1501416a3, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Fri Nov 22 11:52:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512002, encodeId=61e7151200252, content=<a href='/topic/show?id=da82895e077' target=_blank style='color:#2F92EE;'>#血管功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89570, encryptionId=da82895e077, topicName=血管功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a8810427189, createdName=1249859em41(暂无昵称), createdTime=Fri Nov 22 11:52:00 CST 2019, time=2019-11-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1718700, encodeId=10841e1870047, content=<a href='/topic/show?id=a93250e8239' target=_blank style='color:#2F92EE;'>#微血管功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50782, encryptionId=a93250e8239, topicName=微血管功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c032593421, createdName=zz81, createdTime=Wed May 27 23:52:00 CST 2020, time=2020-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018097, encodeId=05c5201809e5f, content=<a href='/topic/show?id=9f53912654e' target=_blank style='color:#2F92EE;'>#认知表现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91265, encryptionId=9f53912654e, topicName=认知表现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Thu Mar 26 04:52:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728203, encodeId=448e1e2820393, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Sep 03 10:52:00 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039123, encodeId=b5d020391230a, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Thu Dec 05 06:52:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365386, encodeId=00a3136538616, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Fri Nov 22 11:52:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421264, encodeId=84af142126477, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Fri Nov 22 11:52:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501416, encodeId=2b5f1501416a3, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Fri Nov 22 11:52:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512002, encodeId=61e7151200252, content=<a href='/topic/show?id=da82895e077' target=_blank style='color:#2F92EE;'>#血管功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89570, encryptionId=da82895e077, topicName=血管功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a8810427189, createdName=1249859em41(暂无昵称), createdTime=Fri Nov 22 11:52:00 CST 2019, time=2019-11-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1718700, encodeId=10841e1870047, content=<a href='/topic/show?id=a93250e8239' target=_blank style='color:#2F92EE;'>#微血管功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50782, encryptionId=a93250e8239, topicName=微血管功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c032593421, createdName=zz81, createdTime=Wed May 27 23:52:00 CST 2020, time=2020-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018097, encodeId=05c5201809e5f, content=<a href='/topic/show?id=9f53912654e' target=_blank style='color:#2F92EE;'>#认知表现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91265, encryptionId=9f53912654e, topicName=认知表现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Thu Mar 26 04:52:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728203, encodeId=448e1e2820393, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Sep 03 10:52:00 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039123, encodeId=b5d020391230a, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Thu Dec 05 06:52:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365386, encodeId=00a3136538616, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Fri Nov 22 11:52:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421264, encodeId=84af142126477, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Fri Nov 22 11:52:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501416, encodeId=2b5f1501416a3, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Fri Nov 22 11:52:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512002, encodeId=61e7151200252, content=<a href='/topic/show?id=da82895e077' target=_blank style='color:#2F92EE;'>#血管功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89570, encryptionId=da82895e077, topicName=血管功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a8810427189, createdName=1249859em41(暂无昵称), createdTime=Fri Nov 22 11:52:00 CST 2019, time=2019-11-22, status=1, ipAttribution=)]
    2020-09-03 feather89
  4. [GetPortalCommentsPageByObjectIdResponse(id=1718700, encodeId=10841e1870047, content=<a href='/topic/show?id=a93250e8239' target=_blank style='color:#2F92EE;'>#微血管功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50782, encryptionId=a93250e8239, topicName=微血管功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c032593421, createdName=zz81, createdTime=Wed May 27 23:52:00 CST 2020, time=2020-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018097, encodeId=05c5201809e5f, content=<a href='/topic/show?id=9f53912654e' target=_blank style='color:#2F92EE;'>#认知表现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91265, encryptionId=9f53912654e, topicName=认知表现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Thu Mar 26 04:52:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728203, encodeId=448e1e2820393, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Sep 03 10:52:00 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039123, encodeId=b5d020391230a, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Thu Dec 05 06:52:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365386, encodeId=00a3136538616, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Fri Nov 22 11:52:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421264, encodeId=84af142126477, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Fri Nov 22 11:52:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501416, encodeId=2b5f1501416a3, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Fri Nov 22 11:52:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512002, encodeId=61e7151200252, content=<a href='/topic/show?id=da82895e077' target=_blank style='color:#2F92EE;'>#血管功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89570, encryptionId=da82895e077, topicName=血管功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a8810427189, createdName=1249859em41(暂无昵称), createdTime=Fri Nov 22 11:52:00 CST 2019, time=2019-11-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1718700, encodeId=10841e1870047, content=<a href='/topic/show?id=a93250e8239' target=_blank style='color:#2F92EE;'>#微血管功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50782, encryptionId=a93250e8239, topicName=微血管功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c032593421, createdName=zz81, createdTime=Wed May 27 23:52:00 CST 2020, time=2020-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018097, encodeId=05c5201809e5f, content=<a href='/topic/show?id=9f53912654e' target=_blank style='color:#2F92EE;'>#认知表现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91265, encryptionId=9f53912654e, topicName=认知表现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Thu Mar 26 04:52:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728203, encodeId=448e1e2820393, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Sep 03 10:52:00 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039123, encodeId=b5d020391230a, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Thu Dec 05 06:52:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365386, encodeId=00a3136538616, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Fri Nov 22 11:52:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421264, encodeId=84af142126477, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Fri Nov 22 11:52:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501416, encodeId=2b5f1501416a3, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Fri Nov 22 11:52:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512002, encodeId=61e7151200252, content=<a href='/topic/show?id=da82895e077' target=_blank style='color:#2F92EE;'>#血管功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89570, encryptionId=da82895e077, topicName=血管功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a8810427189, createdName=1249859em41(暂无昵称), createdTime=Fri Nov 22 11:52:00 CST 2019, time=2019-11-22, status=1, ipAttribution=)]
    2019-11-22 mgqwxj
  6. [GetPortalCommentsPageByObjectIdResponse(id=1718700, encodeId=10841e1870047, content=<a href='/topic/show?id=a93250e8239' target=_blank style='color:#2F92EE;'>#微血管功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50782, encryptionId=a93250e8239, topicName=微血管功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c032593421, createdName=zz81, createdTime=Wed May 27 23:52:00 CST 2020, time=2020-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018097, encodeId=05c5201809e5f, content=<a href='/topic/show?id=9f53912654e' target=_blank style='color:#2F92EE;'>#认知表现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91265, encryptionId=9f53912654e, topicName=认知表现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Thu Mar 26 04:52:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728203, encodeId=448e1e2820393, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Sep 03 10:52:00 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039123, encodeId=b5d020391230a, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Thu Dec 05 06:52:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365386, encodeId=00a3136538616, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Fri Nov 22 11:52:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421264, encodeId=84af142126477, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Fri Nov 22 11:52:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501416, encodeId=2b5f1501416a3, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Fri Nov 22 11:52:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512002, encodeId=61e7151200252, content=<a href='/topic/show?id=da82895e077' target=_blank style='color:#2F92EE;'>#血管功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89570, encryptionId=da82895e077, topicName=血管功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a8810427189, createdName=1249859em41(暂无昵称), createdTime=Fri Nov 22 11:52:00 CST 2019, time=2019-11-22, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1718700, encodeId=10841e1870047, content=<a href='/topic/show?id=a93250e8239' target=_blank style='color:#2F92EE;'>#微血管功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50782, encryptionId=a93250e8239, topicName=微血管功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c032593421, createdName=zz81, createdTime=Wed May 27 23:52:00 CST 2020, time=2020-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018097, encodeId=05c5201809e5f, content=<a href='/topic/show?id=9f53912654e' target=_blank style='color:#2F92EE;'>#认知表现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91265, encryptionId=9f53912654e, topicName=认知表现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Thu Mar 26 04:52:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728203, encodeId=448e1e2820393, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Sep 03 10:52:00 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039123, encodeId=b5d020391230a, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Thu Dec 05 06:52:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365386, encodeId=00a3136538616, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Fri Nov 22 11:52:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421264, encodeId=84af142126477, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Fri Nov 22 11:52:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501416, encodeId=2b5f1501416a3, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Fri Nov 22 11:52:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512002, encodeId=61e7151200252, content=<a href='/topic/show?id=da82895e077' target=_blank style='color:#2F92EE;'>#血管功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89570, encryptionId=da82895e077, topicName=血管功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a8810427189, createdName=1249859em41(暂无昵称), createdTime=Fri Nov 22 11:52:00 CST 2019, time=2019-11-22, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1718700, encodeId=10841e1870047, content=<a href='/topic/show?id=a93250e8239' target=_blank style='color:#2F92EE;'>#微血管功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50782, encryptionId=a93250e8239, topicName=微血管功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c032593421, createdName=zz81, createdTime=Wed May 27 23:52:00 CST 2020, time=2020-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018097, encodeId=05c5201809e5f, content=<a href='/topic/show?id=9f53912654e' target=_blank style='color:#2F92EE;'>#认知表现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91265, encryptionId=9f53912654e, topicName=认知表现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Thu Mar 26 04:52:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728203, encodeId=448e1e2820393, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Sep 03 10:52:00 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039123, encodeId=b5d020391230a, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Thu Dec 05 06:52:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365386, encodeId=00a3136538616, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Fri Nov 22 11:52:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421264, encodeId=84af142126477, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Fri Nov 22 11:52:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501416, encodeId=2b5f1501416a3, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Fri Nov 22 11:52:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512002, encodeId=61e7151200252, content=<a href='/topic/show?id=da82895e077' target=_blank style='color:#2F92EE;'>#血管功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89570, encryptionId=da82895e077, topicName=血管功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a8810427189, createdName=1249859em41(暂无昵称), createdTime=Fri Nov 22 11:52:00 CST 2019, time=2019-11-22, status=1, ipAttribution=)]

相关资讯

JACC Cardiovasc Inte:OCT定义的易损斑块与功能性狭窄程度及微血管障碍相关

众所周知,心外膜病变及微血管功能障碍的严重程度均与不良临床结局具有相关性。JACC:Cardiovascular Interventions发表的一项最新研究探讨不稳定斑块特征与生理病变严重程度及微血管功能障碍的相关性。

Diabetes Care:2型糖尿病、神经病变和微血管功能障碍之间有啥联系?

在本研究中,内皮依赖性血管舒张功能在2型糖尿病患者减少,无论有无多发性神经病变的存在,然而CAP患者微血管舒张功能正常。这些数据表明,在2型糖尿病患者中,神经病变并不有助于血管内皮依赖性血管舒张损伤,反之亦然。此外,这项研究表明,受损的血管舒张作用不会促进CAP。

Heart:微血管功能障碍与HFpEF发病相关

一项研究显示,微血管功能障碍可能参与了射血分数保留心衰(HFpEF)的病理生理过程,而传输动脉功能与HFpEF无关联。Joshua F. Lee(犹他州大学)等研究者假设HFpEF患者存在微血管和传输动脉功能损害,纳入了24名HFpEF患者(NYHA II、III、IV级)和24名年龄、性别和肱动脉直径匹配的健康人,比较了两组的传输动脉功能(肱动脉血流介导的舒张功能)和微血管功能(在5分钟缺血后的

Hypertension:血管紧张素II敏感性的增加促进既往先兆子痫妇女微血管功能障碍!

这些数据表明先兆子痫孕妇在产后持续存在微血管功能障碍,其部分原因是对血管紧张素II的敏感性增加所致。